Advertisement

Cell Biochemistry and Biophysics

, Volume 43, Issue 1, pp 77–85 | Cite as

A new method for targeted drug delivery using polymeric microcapsules

Implications for treatment of crohn's disease
  • Terrence Metz
  • Mitchell L. Jones
  • Hongmei Chen
  • Trisnawati Halim
  • Maryam Mirzaei
  • Tasima Haque
  • Devendra Amre
  • Sujata K. Das
  • Satya Prakash
Original Article

Abstract

Recent research and clinical evidence suggest that thalidomide could potentially be used to treat inflammation associated with Crohn's disease. However, systemic side effects associated with large doses of this drug have limited its widespread use. Treatment, with thalidomide would prove more efficacious if the drug could be delivered directly to target areas in the gut, thereby reducing systemic circulation. Microcapsule encapsulation could enable direct delivery of the drug. To assess the latter, we designed and tested drug-targeting release characteristics of alginate-poly-l-lysine-alginate (APA) microcapsules in simulated gastrointestinal environments. The results show that APA capsules enabled delivery of thalidomide in the middle and distal portions of the small intestine. We also compared the APA membrane formulation with an earlier designed alginate chitosan (AC) membrane thalidomide formulation. The results show that both APA and AC capsules allow for successful delivery of thalidomide in the gut and could prove beneficial in the treatment of Crohn's disease. However, further research is required.

Index Entries

Thalidomide Crohn's disease artificial cells microcapsule inflammatory bowel disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Breese, E. J., Michie, C. A., Nicholls, S. W., et al. (1994) Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106, 1455–1466.PubMedGoogle Scholar
  2. 2.
    Goncalves, N. S., Ghaem-Maghami, M., Monteleone, G., et al. (2001) Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect. Immun. 69, 6651–6659.PubMedCrossRefGoogle Scholar
  3. 3.
    Lilja, I., Gustafson-Svard, C., Franzen, L., and Sjodahl, R. (2000) Tumor necrosis factor-alpha in ileal mast cells in patients with Crohn's disease. Digestion 61, 68–76.PubMedCrossRefGoogle Scholar
  4. 4.
    Murch, S. H., Lamkin, V. A., Savage, M. O., Walker-Smith, J. A., and MacDonald, T. T. (1991) Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32, 913–917.PubMedCrossRefGoogle Scholar
  5. 5.
    van Deventer S. J. (2001) Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 121, 1242–1246.PubMedCrossRefGoogle Scholar
  6. 6.
    Aeberli, D., Oertle, S., Mauron, H., Reichenbach, S., Jordi, B., and Villiger, P. M. (2002) Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders Swiss. Med. Wkly. 132, 414–422.PubMedGoogle Scholar
  7. 7.
    Rutgeerts, P., D'Haens, G., Targan, S., et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117, 761–769.PubMedCrossRefGoogle Scholar
  8. 8.
    Ehrenpreis, E. D., Kane, S. V., Cohen, L. B., Cohen, R. D., and Hanauer, S. B. (1999) Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117, 1271–1277.PubMedCrossRefGoogle Scholar
  9. 9.
    Gardner-Medwin, J. M., Smith, N. J., and Powell, R. J. (1994) Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheum. Dis. 53, 828–832.PubMedGoogle Scholar
  10. 10.
    Keifer, J. A., Guttridge, D. C., Ashburner, B. P., and Baldwin, A. S. Jr. (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem. 276, 22,382–22,387.CrossRefGoogle Scholar
  11. 11.
    Ochonisky, S., Verroust, J., Bastuji-Garin, S., Gherardi, R., and Revuz, J. (1994) Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch. Dermatol. 130, 66–69.PubMedCrossRefGoogle Scholar
  12. 12.
    Sabate, J. M., Villarejo, J., Lemann, M., Bonnet, J., Allez, M., and Modigliani, R. (2002) An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment. Pharmacol. Ther. 16, 1117–1124.PubMedCrossRefGoogle Scholar
  13. 13.
    Vasiliauskas, E. A., Kam, L. Y., Abreu-Martin, M. T., et al. (1999) An open-label pilot study of lowdose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117, 1278–1287.PubMedCrossRefGoogle Scholar
  14. 14.
    Odeka, E. B. and Miller, V. (1997) Thalidomide in oral Crohn's disease refractory to conventional medical treatment. J. Pediatr. Gastroenterol. Nutr. 25, 250–251.CrossRefGoogle Scholar
  15. 15.
    Wettstein, A. R. and Meagher, A. P. (1997) Thalidomide in Crohn's disease. Lancet 350, 1445, 1446.PubMedCrossRefGoogle Scholar
  16. 16.
    Brocvielle, H., Muret, P., Plenat, E., Kantelip, J. P., and Humbert, P. (2003) Management of a patient receiving thalidomide. Presse Med. 32, 1894–1898.PubMedGoogle Scholar
  17. 17.
    Valero, F. C. and Gonzalez, V. B. (2002) Lung toxicity due to thalidomide. Arch. Bronconeumol. 38, 492–494.Google Scholar
  18. 18.
    Aeberli, D., Oertle, S., Mauron, H., Reichenbach, S., Jordi, B., and Villiger P. M. (2002) Inhibition of the TNF pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med. Wkly. 132, 414–422.PubMedGoogle Scholar
  19. 19.
    Bariol, C., Meagher, A. P., Vickers, C. R., et al. (2002) Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J. Gastroenterol. Hepatol. 17, 135–139.PubMedCrossRefGoogle Scholar
  20. 20.
    Chang, T. M. (1999) Artificial cells, encapsulation, and immobilization. Ann. NY Acad. Sci. 875, 71–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Chang, T. M. (1998) Artificial cells with emphasis on cell encapsulation of genetically engineered cells. Artif. Organs 22, 958–965.PubMedCrossRefGoogle Scholar
  22. 22.
    Chang, T. M. and Prakash, S. (1998) Therapeutic uses of microencapsulated genetically engi-neered cells. Mol. Med. Today 4, 221–227.PubMedCrossRefGoogle Scholar
  23. 23.
    Metz, T. (2003) Polymer microcapsules for targeted oral drug delivery in Crohn's disease. Ann. Can. Biomater. Soc. 1, 89.Google Scholar
  24. 24.
    Metz, T., Amre, D., Chen, H., Ouyang, W., Haque, T., Martoni, C., and Prakash, S. (2004) Artificial cells containing thalidomide as an alternative oral therapy method for Crohn's disease. Gastroenterology 126, A288.Google Scholar
  25. 25.
    Ehrenpreis, E. D., Kane, S. V., Cohen, L. B., Cohen, R. D., and Hanauer, S. B. (1999) Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117, 1271–1277.PubMedCrossRefGoogle Scholar
  26. 26.
    Facchini, S., Candusso, M., Martelossi, S. Liubich, M., Panfili, E., and Ventura, A. (2001) Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J. Pediatr. Gastroenterol. Nutr. 32, 178–181.PubMedCrossRefGoogle Scholar
  27. 27.
    Hegarty, A., Hodgson, T., and Porter, S. (2003) Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95, 576–585.PubMedCrossRefGoogle Scholar
  28. 28.
    Kolivras, A., De Maubeuge, J., Andre, J., and Song, M. (2003) Thalidomide in refractory vulvar ulcerations associated with Crohn's disease. Dermatology 206, 381–383.PubMedCrossRefGoogle Scholar
  29. 29.
    Sabate, J. M., Villarejo, J., Lemann, M., Bonnet, J., Allez, M., and Modigliani, R. (2002) An openlabel study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment. Pharmacol. Ther. 16, 1117–1124.PubMedCrossRefGoogle Scholar
  30. 30.
    Bariol, C., Meagher, A. P., Vickers C. R., et al. (2002) Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J. Gastroenterol. Hepatol. 17, 135–139.PubMedCrossRefGoogle Scholar
  31. 31.
    Kho, Y. H., Pool, M. O., Jansman, F. G. A., and Harting, J. W. (2001) Pharmacotherapeutical options in inflammatory bowel disease an update. Pharm. World Sci. 23, 17–21.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  • Terrence Metz
    • 1
  • Mitchell L. Jones
    • 1
  • Hongmei Chen
    • 1
  • Trisnawati Halim
    • 1
  • Maryam Mirzaei
    • 1
  • Tasima Haque
    • 1
  • Devendra Amre
    • 2
  • Sujata K. Das
    • 3
  • Satya Prakash
    • 1
  1. 1.Biomedical Technology and Cell Therapy Research Laboratory Department of Biomedical Engineering and Physiology, Artificial Cells & Organs Research Center, Faculty of MedicineMcGill UniversityMontrealCanada
  2. 2.Sainte-Justine HospitalUniversity of MontrealMontrealCanada
  3. 3.Division of Endocrinology, Department of Obstetrics and Gynecology The N.Y. HospitalCornell University Medical CenterNew York

Personalised recommendations